BeSound Launches Cutting-Edge Breast Screening Clinic in NYC

BeSound, a pioneering company in the realm of breast imaging, has officially inaugurated its flagship location in the bustling Flatiron district of New York City. This innovative facility is dedicated to revolutionizing breast cancer screening through the use of its FDA-approved 3D automated breast ultrasound (ABUS) technology.

Founded by Bailey Renger, a former NASA physicist, BeSound aims to address a critical gap in breast cancer detection, particularly among women with dense breast tissue, where traditional mammograms often fall short. The ABUS technology captures standardized, full-volume 3D images of the breast, ensuring a consistent level of quality and detail that enhances diagnostic accuracy. This remarkable approach not only eliminates the discomfort associated with traditional mammograms but also provides a radiation-free alternative, improving accessibility to vital screening services.

Women can experience a seamless process when booking an appointment at BeSound. With no need for a referral, patients can schedule their appointments online within minutes, often securing same-day slots. Results are typically delivered within 24 to 48 hours, making the experience efficient and comforting for those seeking early detection of breast cancer.

One of the distinguishing features of BeSound's technology is its integration with a sophisticated AI layer that learns from each exam conducted. This AI component aids physicians in interpreting scans more effectively, allowing for quicker identification of abnormalities and enabling better long-term tracking of a woman’s breast health. Renger emphasizes that this innovation empowers women by encouraging proactive health management rather than reactive measures.

The Invenia™ ABUS technology, produced by GE HealthCare, is a key element of BeSound’s offerings. Not only is it the first FDA-approved ultrasound screening technology aimed specifically at detecting cancers in dense breast tissue, but it has also been clinically shown to detect 55% more invasive cancers compared to mammograms alone. This dramatic increase in accuracy underscores the importance of BeSound’s mission to enhance early detection, which is critical in improving survival rates among women diagnosed with breast cancer.

Statistically, when breast cancer is detected at an early, localized stage, the five-year relative survival rate exceeds an impressive 99%. However, late-stage detection drastically decreases these odds due to the cancer spreading beyond the initial site. BeSound’s proactive model positions women to understand their individual risks and access the necessary imaging to detect cancer before it becomes more serious.

With plans to expand its services further by the end of 2026, BeSound anticipates making insurance-covered screenings available through numerous payers within New York and other growing markets. The company is also looking to implement a mobile van service to bring these screenings into underserved communities, enhancing accessibility and promoting preventive care.

For those eager to learn more or to schedule an appointment, the BeSound website offers a user-friendly experience for setting up consultations. Additionally, followers can stay connected with BeSound through their social media platforms, including Instagram at @besoundbreast.

As society shifts towards more advanced and patient-oriented healthcare solutions, BeSound stands at the forefront of this transformation, championing a future where no woman is left without the preventative care she needs. This forward-thinking approach not only improves technology in medical imaging but also seeks to foster a culture of proactive breast health that can ultimately save lives.